Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40586640

about

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Virotherapy: cancer gene therapy at last?A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKs Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact.Increasing the efficacy of oncolytic adenovirus vectors Development of viral vectors for gene therapy for chronic pain Parvovirus vectors for cancer gene therapy.Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)Oncolytic virotherapy for advanced liver tumours.Oncolytic viral therapies.Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.Oncolytic viruses in the treatment of bladder cancer Gene- and immunotherapy for hepatocellular carcinoma.Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus Recent clinical progress in virus-based therapies for cancer.Immunotherapy for liver tumors: present status and future prospects.Oncolytic (replication-competent) adenoviruses as anticancer agents.AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?Clinical development directions in oncolytic viral therapy.Utilizing adenovirus vectors for gene delivery in cancer.Local drug delivery to a human pancreatic tumor via a newly designed multiple injectable needle.Potential usefulness of baculovirus-mediated sodium-iodide symporter reporter gene as non-invasively gene therapy monitoring in liver cancer cells: an in vitro evaluation.Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma.Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.Gene therapy of liver cancer.Review: Oncolytic virotherapy, updates and future directions.

P2860

Q27001601-6AAAC0C5-0B03-40AC-9489-F4EFB5CE4D95 Q28066228-17ED5CBB-E5ED-4E66-832C-76B786F43F26 Q28477181-29057BFC-B6A6-4AD3-893D-BFE4CAF3FA17 Q33635033-BEA89277-20AA-4AF3-BBA8-907389CDD4E3 Q34681207-3FF59ABD-D69B-40C2-A0C1-656FBC177C7F Q35043106-82C9DE37-5AF9-4BEC-88EA-138368DE9216 Q35145614-7FD784A9-0225-48E6-B6FA-D1A038D649F4 Q35208038-3103CC5B-A7DC-423A-B1F2-E6BD453ED6E1 Q35261325-E8AC1178-2D1C-4F1D-85D0-A4C7E44CFADB Q35430864-46B881F6-1B49-44EA-ABAE-DAAC28248721 Q35609780-E9157A33-A256-4338-87DE-4FF500A5C3B5 Q35809215-35D940C5-A7E2-4E95-8689-109B33011F08 Q35832074-44E0183C-AEC5-4364-93E3-9DDBED9CD176 Q35852258-B52CCE98-6B7E-43D2-9A8C-36A5695E1951 Q35883639-E63BE4D1-DDFD-4A20-93AB-E79DCB5EE9B8 Q36147934-D5E5C7FF-66A3-48F9-9743-99B73B6D77F3 Q36150432-8940EBE1-5339-4905-8B7E-6F2EBF280579 Q36184357-9E606C45-7C03-4766-90C0-B44A9E32B3B6 Q36627242-BAC0FB39-5125-4852-B90D-6CF9D3EB116C Q37144014-D12CB8DA-161C-4186-A552-72545D4B26CC Q37687415-AECEA55F-D8C1-40FB-9D24-E0948FE40D20 Q37825907-9BB8EFD4-F18F-48E6-8945-25FA9441947E Q37857659-57FBACCE-AB2C-413A-BEEC-E41AF2B0F30B Q38176044-38097E92-B532-450A-82F6-36469EC2096F Q38292643-E55CFCA2-A32D-4762-BBD4-9D2C45E8BFDA Q39114748-4C397BE5-EAA6-4607-919D-0152485C6931 Q39235688-B2EBF4E1-22B2-4BE4-B07B-D1683E35EECE Q39807606-B038620F-7BBC-48E1-8252-779A8EA9F589 Q40008652-DFEAEB70-32CE-4A5D-BD54-ADF9BF5B1457 Q40424880-E913463F-4DA2-4EDF-99F4-20814F1FDE0E Q40515050-E9DFE52B-6C9F-4BEE-B98A-AC5D217AE54D Q40663869-0BC11D24-09A4-422F-888A-280323A74CA5 Q42726362-ABE0EE17-417C-4CAD-A08B-E2E0D2064096 Q47160989-80EC8EBA-5D29-4923-9E04-31D805D87355

P2860

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q40586640

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Clinical trial of E1B-deleted ...... for hepatocellular carcinoma.

@en

type

label

Clinical trial of E1B-deleted ...... for hepatocellular carcinoma.

@en

prefLabel

Clinical trial of E1B-deleted ...... for hepatocellular carcinoma.

@en

P1433

Q40586640-D9D36986-2A3B-46E6-9E91-13E6198F0449

P1476

Q40586640-F9C69F78-1E5B-4B27-9862-7780B25B7B72

P2093

Q40586640-1B0620B0-4A19-4418-8B4B-2F996C310438

Q40586640-1D81A23E-90FF-4ED4-AB0F-7D64A236378E

Q40586640-1F0977DC-0A77-40E8-BD9C-0990006CE7D8

Q40586640-2C66FCA4-9246-4B85-AB13-FD539FD9BF61

Q40586640-3DC35FAB-C573-424B-A6E2-B7C3627FBED2

Q40586640-591E34C6-7F6D-410B-86BF-CB1952DAC006

Q40586640-6BE319D0-9EF3-4D4D-9E51-9BC960D9CB9B

Q40586640-A4DFD026-639A-4294-B529-7BE89A86C142

Q40586640-B2CC96FC-2B8E-4EEF-91C7-883C95FC3DA3

Q40586640-C0807062-9B7E-42BC-AF27-340ECCB9D134

P2860

Q40586640-19AD7A2B-755D-4067-A483-8AA383F4F98E

Q40586640-1DE33899-B2D3-4D09-BAB0-425ECEDB9205

Q40586640-31F30A16-BF35-4477-BA7B-FB75B86B798F

Q40586640-81843172-0256-4B95-A8C7-F39E66C06F1A

Q40586640-993C2A8D-79CE-4476-A2DE-D675337B574D

Q40586640-9F02CF5D-9D58-4663-AB21-477D5092752B

Q40586640-A33DFEFD-D0EE-4D47-8986-A899755E1AD0

Q40586640-AB28F0E7-064F-4BF6-800A-A2D2157E48B2

Q40586640-D785B48D-8F49-42B4-9BA9-0E613A550048

Q40586640-F7F14881-8EEF-40D4-AA76-05F68E831633

P2888

Q40586640-2B5DECDA-73B5-4449-A162-C0048448808F

P304

Q40586640-2D30B230-D1A6-4049-ABED-A088911E4A76

P31

Q40586640-5135A705-AB6C-42CA-BDE0-6D4AB4F6CE9C

P356

Q40586640-33DDCADF-6A64-49A8-ACFF-03EBDCB73A15

P433

Q40586640-80F074F8-2D8D-4422-BE77-1F165C8CAA8F

P478

Q40586640-6938001C-6CB8-4DBA-B16E-9BE4CFF5FCEE

P577

Q40586640-4E23C171-0C36-4DDD-A0BF-156AF9C2026B

P5875

Q40586640-23CB5CDD-202E-4BA5-89E3-DD7A9C3E8A3F

P6179

Q40586640-2F646DF6-56B8-409E-93C2-2FDA9905D7FD

P698

Q40586640-DE14C3A3-DDF2-4CF9-A1A3-B9FB53B352DA

P921

Q40586640-7308D7A4-D68A-48BF-9067-3AE90AD7AB2A

Q40586640-89F73EC5-BD21-4DDD-A03E-D697D60D17C8

P356

P1433

Cancer Gene Therapy

P1476

Clinical trial of E1B-deleted ...... for hepatocellular carcinoma.

@en

P2093

Ahmed Abd El Latif Abu Median

http://www.w3.org/2001/XMLSchema#string

Catherine Sarraf

http://www.w3.org/2001/XMLSchema#string

Hosny Salama

http://www.w3.org/2001/XMLSchema#string

Ilia Isac Anis

http://www.w3.org/2001/XMLSchema#string

Jack Hartwigsen

http://www.w3.org/2001/XMLSchema#string

Joanna Nicholls

http://www.w3.org/2001/XMLSchema#string

Nagy Habib

http://www.w3.org/2001/XMLSchema#string

Prem Seth

http://www.w3.org/2001/XMLSchema#string

Ragai Mitry

http://www.w3.org/2001/XMLSchema#string

Rasha Ahmed Abd Al Aziz

http://www.w3.org/2001/XMLSchema#string

P2860

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.

Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection.

p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.

The molecular genetics of cancer.

Treatment of hepatocellular carcinoma: too many options?

Surgical management of hepatocellular carcinoma: resection or transplantation?

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma.

P2888

P304

254-259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CGT.7700431

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11467982

http://www.w3.org/2001/XMLSchema#string

P6179

1011742175

http://www.w3.org/2001/XMLSchema#string

P698

11896441

http://www.w3.org/2001/XMLSchema#string

P921